Intraoperative pediatric blood transfusion therapy: A review of common issues. Part II: Transfusion therapy, special considerations, and reduction of allogenic blood transfusions

Paediatric Anaesthesia

Volumn 15, Issue 10, 2005, Pages 814-830

  Barcelona, Sandra L ^a,b   Thompson, Alexis A ^a,b   Coté, Charles J ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

Blood transfusion: massive; Coagulopathy; Recombinant factor seven (rFVIIa); Thrombocytopenia

Indexed keywords

AMINOCAPROIC ACID; APROTININ; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DESMOPRESSIN; ERYTHROPOIETIN; IMMUNOSUPPRESSIVE AGENT; KETOROLAC; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; TRANEXAMIC ACID; BLOOD CLOTTING FACTOR 7; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADENOIDECTOMY; ALLERGIC REACTION; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD DONOR; BLOOD TRANSFUSION; BURN; CELL SALVAGE; CHILD; DRUG INDICATION; HEART SURGERY; HUMAN; INFANT; INJURY; INTRAOPERATIVE PERIOD; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NEUROSURGERY; NEWBORN; ORTHOPEDIC SURGERY; PATIENT MONITORING; PREMATURITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TONSILLECTOMY; DISSEMINATED INTRAVASCULAR CLOTTING; HEMOSTASIS; METHODOLOGY; PEROPERATIVE CARE; POSTOPERATIVE COMPLICATION;

BLOOD TRANSFUSION; DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR VII; HEMORRHAGE; HEMOSTASIS, SURGICAL; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INTRAOPERATIVE CARE; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; TONSILLECTOMY; WOUNDS AND INJURIES;

EID: 33644700810     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2004.01549.x     Document Type: Review

References (150)

1. Coté CJ, Liu LM, Szyfelbein SK et al. Changes in serial platelet counts following massive blood transfusion in pediatric patients. Anesthesiology 1985 62: 197 201.
2. Coté CJ. Blood, colloid, and crystalloid therapy. Anesth Clin North Am 1991 9: 865 884.
3. Barcelona SL, Coté CJ. Pediatric resuscitation in the operating room. Anesthesiol Clin North Am 2001 19: 339 365.
4. Miller RD. Complications of massive blood transfusions. Anesthesiology 1973 39: 82 93.
5. Butenas S, Brummel KE, Bouchard BA et al. How factor VIIa works in hemophilia. J Thromb Haemost 2003 1: 1158 1160.
6. Schlesinger KW, Ragni MV. Safety of the new generation recombinant factor concentrates. Expert Opin Drug Saf 2002 1: 213 223.
7. Shapiro AD. Recombinant factor VIIa in the treatment of bleeding in hemophilic children with inhibitors. Semin Thromb Hemost 2000 26: 413 419.
8. Seremetis S. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors. Blood Coagul Fibrinolysis 2003 14 Suppl 1: S29 S30.
9. Dejgaard A. Update on Novo Nordisk's clinical trial programme on NovoSeven. Blood Coagul Fibrinolysis 2003 14 Suppl. 1: S39 S41.
10. Girard TJ, Nicholson NS. The role of tissue factor/factor VIIa in the pathophysiology of acute thrombotic formation. Curr Opin Pharmacol 2001 1: 159 163.
11. Midathada MV, Mehta P, Waner M et al. Recombinant factor VIIa in the treatment of bleeding. Am J Clin Pathol 2004 121: 124 137.
12. Gerotziafas GT, Chakroun T, Depasse F et al. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 2004 91: 977 985.
13. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003 361: 161 169.
14. Drews RE. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients. Clin Chest Med 2003 24: 607 622.
15. Laurian Y. Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa Pathophysiol Haemost Thromb 2002 32 Suppl. 1: 37 40.
16. Lynn M, Jeroukhimov I, Klein Y et al. Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med 2002 28 Suppl 2: S241 S247.
17. Jurlander B, Thim L, Klausen NK et al. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development. Semin Thromb Hemost 2001 27: 373 384.
18. Poon MC. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa Curr Hematol Rep 2003 2: 139 147.
19. Kjalke M, Ezban M, Monroe DM et al. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 2001 114: 114 120.
20. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998 19: 163 176.
21. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000 26: 385 391.
22. Abshire TC. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing. Semin Hematol 2004 41 Suppl. 1: 3 7.
23. Martinowitz U, Kenet G, Lubetski A et al. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002 49: S15 S20.
24. Al Douri M, Shafi T, Al Khudairi D et al. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000 11 Suppl. 1: S121 S127.
25. White B, McHale J, Ravi N et al. Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 1999 107: 677 678.
26. O'Neill PA, Bluth M, Gloster ES et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002 52: 400 405.
27. Markiewicz M, Kalicinski P, Kaminski A et al. Acute coagulopathy after reperfusion of the liver graft in children correction with recombinant activated factor VII. Transplant Proc 2003 35: 2318 2319.
28. Naik VN, Mazer CD, Latter DA et al. Successful treatment using recombinant factor VIIa for severe bleeding post cardiopulmonary bypass. Can J Anaesth 2003 50: 599 602.
29. Dutton RP, Hess JR, Scalea TM. Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. J Clin Anesth 2003 15: 184 188.
30. Eikelboom JW, Bird R, Blythe D et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 2003 14: 713 717.
31. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb 2002 32 Suppl. 1: 41 46.
32. Meijer K, Hendriks HG, de Wolf JT et al. Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. Blood Coagul Fibrinolysis 2003 14: 169 174.
33. Morenski JD, Tobias JD, Jimenez DF. Recombinant activated factor VII for cerebral injury-induced coagulopathy in pediatric patients. Report of three cases and review of the literature. J Neurosurg 2003 98: 611 616.
34. Martinowitz U, Kenet G, Segal E et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001 51: 431 438.
35. Martinowitz U, Holcomb JB, Pusateri AE et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001 50: 721 729.
36. Surudo T, Wojcicki M, Milkiewicz P et al. Rapid correction of prothrombin time after low-dose recombinant factor VIIA in patients undergoing orthotopic liver transplantation. Transplant Proc 2003 35: 2323 2325.
37. Gabriel DA, Carr M, Roberts HR. Monitoring coagulation and the clinical effects of recombinant factor VIIa. Semin Hematol 2004 41 Suppl. 1: 20 24.
38. Rajwal S, Richards M, O'Meara M. The use of recalcified citrated whole blood - a pragmatic approach for thromboelastography in children. Paediatr Anaesth 2004 14: 656 660.
39. Srinivasa V, Gilbertson LI, Bhavani-Shankar K. Thromboelastography: where is it and where is it heading Int Anesthesiol Clin 2001 39: 35 49.
40. Whitten CW, Greilich PE. Thromboelastography: past, present, and future. Anesthesiology 2000 92: 1223 1225.
41. Dunkley SM, Mackie F. Recombinant factor VIIa used to control massive haemorrhage during renal transplantation surgery; vascular graft remained patent. Hematology 2003 8: 263 264.
42. Tobias JD, Berkenbosch JW, Muruve NA et al. Correction of a coagulopathy using recombinant factor VII before removal of an intra-aortic balloon pump. J Cardiothorac Vasc Anesth 2002 16: 612 614.
43. Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med 2003 4: 49 51.
44. Pychynska-Pokorska M, Moll JJ, Krajewski W et al. The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. Pediatr Crit Care Med 2004 5: 246 250.
45. Egan JR, Lammi A, Schell DN et al. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med 2003 30: 682 685.
46. Brown JB, Emerick KM, Brown DL et al. Recombinant factor VIIa improves coagulopathy caused by liver failure. J Pediatr Gastroenterol Nutr 2003 37: 268 272.
47. Chuansumrit A, Visanuyothin N, Puapunwattana S et al. Outcome of intracranial hemorrhage in infants with congenital factor VII deficiency. J Med Assoc Thai 2002 85 Suppl. 4: S1059 S1064.
48. Chuansumrit A, Chantarojanasiri T, Isarangkura P et al. Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2000 11 Suppl. 1: S101 S105.
49. Almeida AM, Khair K, Hann I et al. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003 121: 477 481.
50. Veldman A, Fischer D, Voigt B et al. Life-threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med 2002 28: 1635 1637.
51. Greisen G, Andreasen RB. Recombinant factor VIIa in preterm neonates with prolonged prothrombin time. Blood Coagul Fibrinolysis 2003 14: 117 120.
52. Sauaia A, Moore FA, Moore EE et al. Epidemiology of trauma deaths: a reassessment. J Trauma 1995 38: 185 193.
53. Pinsky MR. Probing the limits of arterial pulse contour analysis to predict preload responsiveness. Anesth Analg 2003 96: 1245 1247.
54. Idris A, Melker RJ. High-flow sheaths for pediatric fluid resuscitation: a comparison of flow rates with standard pediatric catheters. Pediatr Emerg Care 1992 8: 119 122.
55. Goldstein B, Doody D, Briggs S. Emergency intraosseous infusion in severely burned children. Pediatr Emerg Care 1990 6: 195 197.
56. Tighe SQ, Rudland SV, Kemp PM et al. Paediatric resuscitation in adverse circumstances: a comparison of three routes of systemic access. J R Nav Med Serv 1993 79: 75 79.
57. Velasco AL, Delgado-Paredes C, Templeton J et al. Intraosseous infusion of fluids in the initial management of hypovolemic shock in young subjects. J Pediatr Surg 1991 26: 4 8.
58. Wade CE, Grady JJ, Kramer GC. Efficacy of hypertonic saline dextran fluid resuscitation for patients with hypotension from penetrating trauma. J Trauma 2003 54 Suppl. 5: S144 S148.
59. Wade CE, Grady JJ, Kramer GC et al. Individual patient cohort analysis of the efficacy of hypertonic saline/dextran in patients with traumatic brain injury and hypotension. J Trauma 1997 42 Suppl. 5: S61 S65.
60. Maningas PA, Mattox KL, Pepe PE et al. Hypertonic saline-dextran solutions for the prehospital management of traumatic hypotension. Am J Surg 1989 157: 528 533.
61. Stump DC, Strauss RG, Henriksen RA et al. Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 1985 25: 349 354.
62. Strauss RG, Stump DC, Henriksen RA et al. Effects of hydroxyethyl starch on fibrinogen, fibrin clot formation, and fibrinolysis. Transfusion 1985 25: 230 234.
63. Patt A, McCroskey BL, Moore EE. Hypothermia-induced coagulopathies in trauma. Surg Clin North Am 1988 68: 775 785.
64. Counts RB, Haisch C, Simon TL et al. Hemostasis in massively transfused trauma patients. Ann Surg 1979 190: 91 99.
65. Murray DJ, Olson J, Strauss R et al. Coagulation changes during packed red cell replacement of major blood loss. Anesthesiology 1988 69: 839 845.
66. Coté CJ. Changes in prothrombin and partial thromboplastin times during massive blood loss in children undergoing Harrington rod instrumentation. Section on Anesthesiology. American Academy of Pediatrics, 1988.
67. Murray DJ, Pennell BJ, Weinstein SL et al. Packed red cells in acute blood loss: dilutional coagulopathy as a cause of surgical bleeding. Anesth Analg 1995 80: 336 342.
68. Cohen A, Manno C. Transfusion practices in infants receiving assisted ventilation. Clin Perinatol 1998 25: 97 111.
69. Warren LJ, Simmer K, Roxby D et al. DNA polymorphism analysis in transfusion-associated graft-versus-host disease. J Paediatr Child Health 1999 35: 98 101.
70. Floss AM, Strauss RG, Goeken N et al. Multiple transfusions fail to provoke antibodies against blood cell antigens in human infants. Transfusion 1986 26: 419 422.
71. Manno CS. What's new in transfusion medicine Pediatr Clin North Am 1996 43: 793 808.
72. DePalma L, Yu M, McIntosh CL et al. Changes in lymphocyte subpopulations as a result of cardiopulmonary bypass. The effect of blood transfusion. J Thorac Cardiovasc Surg 1991 101: 240 244.
73. Colon-Otero G, Gilchrist GS, Holcomb GR et al. Preoperative evaluation of hemostasis in patients with congenital heart disease. Mayo Clin Proc 1987 62: 379 385.
74. Gill JC, Wilson AD, Endres-Brooks J et al. Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects. Blood 1986 67: 758 761.
75. Chambers LA, Cohen DM, Davis JT. Transfusion patterns in pediatric open heart surgery. Transfusion 1996 36: 150 154.
76. Petaja J, Lundstrom U, Leijala M et al. Bleeding and use of blood products after heart operations in infants. J Thorac Cardiovasc Surg 1995 109: 524 529.
77. Kern FH, Morana NJ, Sears JJ et al. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg 1992 54: 541 546.
78. Miller BE, Mochizuki T, Levy JH et al. Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth Analg 1997 85: 1196 1202.
79. Williams GD, Bratton SL, Ramamoorthy C. Factors associated with blood loss and blood product transfusions: a multivariate analysis in children after open-heart surgery. Anesth Analg 1999 89: 57 64.
80. von Segesser LK, Tozzi P, Mallbiabrrena I et al. Miniaturization in cardiopulmonary bypass. Perfusion 2003 18: 219 224.
81. Friesen RH, Campbell DN, Clarke DR et al. Modified ultrafiltration attenuates dilutional coagulopathy in pediatric open heart operations. Ann Thorac Surg 1997 64: 1787 1789.
82. Friesen RH, Tornabene MA, Coleman SP. Blood conservation during pediatric cardiac surgery: ultrafiltration of the extracorporeal circuit volume after cardiopulmonary bypass. Anesth Analg 1993 77: 702 707.
83. Stein JI, Gombotz H, Rigler B et al. Open heart surgery in children of Jehovah's Witnesses: extreme hemodilution on cardiopulmonary bypass. Pediatr Cardiol 1991 12: 170 174.
84. Mossad E, Estafanous F. Blood use in cardiac surgery and the limitations of hemodilution. Curr Opin Cardiol 1995 10: 584 590.
85. Fukumura F, Sese A, Ueno Y et al. Haemostatic profile of small children during and following cardiopulmonary bypass. Jpn J Thorac Cardiovasc Surg 2003 51: 577 581.
86. Nakamura Y, Masuda M, Toshima Y et al. Comparative study of cell saver and ultrafiltration nontransfusion in cardiac surgery. Ann Thorac Surg 1990 49: 973 978.
87. Dittrich S, Aktuerk D, Seitz S et al. Effects of ultrafiltration and peritoneal dialysis on proinflammatory cytokines during cardiopulmonary bypass surgery in newborns and infants. Eur J Cardiothorac Surg 2004 25: 935 940.
88. Ootaki Y, Yamaguchi M, Yoshimura N et al. Efficacy of a criterion-driven transfusion protocol in patients having pediatric cardiac surgery. J Thorac Cardiovasc Surg 2004 127: 953 958.
89. Mossinger H, Dietrich W, Braun SL et al. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg 2003 75: 430 437.
90. Pouard P. Review of efficacy parameters. Ann Thorac Surg 1998 65 Suppl. 6: S40 S43.
91. Huang H, Ding W, Su Z et al. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 1993 106: 11 18.
92. Coniff RF. The Bayer 022 compassionate-use pediatric study. Ann Thorac Surg 1998 65 Suppl. 6: S31 S33.
93. Boldt J, Knothe C, Zickmann B et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss. J Thorac Cardiovasc Surg 1993 105: 705 711.
94. Ranucci M, Corno A, Pavesi M et al. Renal effects of low dose aprotinin in pediatric cardiac surgery. Minerva Anestesiol 1994 60: 361 366.
95. Dobkowski WB, Murkin JM. A risk-benefit assessment of aprotinin in cardiac surgical procedures. Drug Saf 1998 18: 21 41.
96. Cohen DM, Norberto J, Cartabuke R et al. Severe anaphylactic reaction after primary exposure to aprotinin. Ann Thorac Surg 1999 67: 837 838.
97. Carrel TP, Schwanda M, Vogt PR et al. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only. Ann Thorac Surg 1998 66: 153 158.
98. D'Errico CC. Pharmacoeconomics analysis in a pediatric population. Ann Thorac Surg 1998 65 Suppl. 6: S52 S54.
99. Mossinger H, Dietrich W. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. Ann Thorac Surg 1998 65 Suppl. 6: S45 S50.
100. Dietrich W. Incidence of hypersensitivity reactions. Ann Thorac Surg 1998 65 Suppl. 6: S60 S64.
101. Dietrich W, Spath P, Ebell A et al. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J Thorac Cardiovasc Surg 1997 113: 194 201.
102. Handler SD, Miller L, Richmond KH et al. Post-tonsillectomy hemorrhage: incidence, prevention and management. Laryngoscope 1986 96: 1243 1247.
103. Crysdale WS, Russel D. Complications of tonsillectomy and adenoidectomy in 9409 children observed overnight. CMAJ 1986 135: 1139 1142.
104. Wei JL, Beatty CW, Gustafson RO. Evaluation of posttonsillectomy hemorrhage and risk factors. Otolaryngol Head Neck Surg 2000 123: 229 235.
105. Postma DS, Folsom F. The case for an outpatient ''approach'' for all pediatric tonsillectomies and/or adenoidectomies: a 4-year review of 1419 cases at a community hospital. Otolaryngol Head Neck Surg 2002 127: 101 108.
106. Asaf T, Reuveni H, Yermiahu T et al. The need for routine pre-operative coagulation screening tests (prothrombin time PT/partial thromboplastin time PTT) for healthy children undergoing elective tonsillectomy and/or adenoidectomy. Int J Pediatr Otorhinolaryngol 2001 61: 217 222.
107. Zwack GC, Derkay CS. The utility of preoperative hemostatic assessment in adenotonsillectomy. Int J Pediatr Otorhinolaryngol 1997 39: 67 76.
108. Krishna P, Lee D. Post-tonsillectomy bleeding: a meta-analysis. Laryngoscope 2001 111: 1358 1361.
109. Close HL, Kryzer TC, Nowlin JH et al. Hemostatic assessment of patients before tonsillectomy: a prospective study. Otolaryngol Head Neck Surg 1994 111: 733 738.
110. Lippi G, Manzato F, Franchini M et al. Establishment of reference values for the PFA-100 platelet function analyzer in pediatrics. Clin Exp Med 2001 1: 69 70.
111. Fressinaud E, Veyradier A, Truchaud F et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998 91: 1325 1331.
112. Derkay CS, Werner E, Plotnick E. Management of children with von Willebrand disease undergoing adenotonsillectomy. Am J Otolaryngol 1996 17: 172 177.
113. Judkins JH, Dray TG, Hubbell RN. Intraoperative ketorolac and posttonsillectomy bleeding. Arch Otolaryngol Head Neck Surg 1996 122: 937 940.
114. Splinter WM, Rhine EJ, Roberts DW et al. Preoperative ketorolac increases bleeding after tonsillectomy in children. Can J Anaesth 1996 43: 560 563.
115. Gunter JB, Varughese AM, Harrington JF et al. Recovery and complications after tonsillectomy in children: a comparison of ketorolac and morphine. Anesth Analg 1995 81: 1136 1141.
116. Gallagher JE, Blauth J, Fornadley JA. Perioperative ketorolac tromethamine and postoperative hemorrhage in cases of tonsillectomy and adenoidectomy. Laryngoscope 1995 105: 606 609.
117. Rusy LM, Houck CS, Sullivan LJ et al. A double-blind evaluation of ketorolac tromethamine versus acetaminophen in pediatric tonsillectomy: analgesia and bleeding. Anesth Analg 1995 80: 226 229.
118. Romsing J, Ostergaard D, Walther-Larsen S et al. Analgesic efficacy and safety of preoperative versus postoperative ketorolac in paediatric tonsillectomy. Acta Anaesthesiol Scand 1998 42: 770 775.
119. Agrawal A, Gerson CR, Seligman I et al. Postoperative hemorrhage after tonsillectomy: use of ketorolac tromethamine. Otolaryngol Head Neck Surg 1999 120: 335 339.
120. Kovesi T, Royston D. Pharmacological approaches to reducing allogeneic blood exposure. Vox Sang 2003 84: 2 10.
121. Goobie SM, Soriano SG, Zurakowski D et al. Hemostatic changes in pediatric neurosurgical patients as evaluated by thrombelastograph. Anesth Analg 2001 93: 887 892.
122. Curreri PW, Hicks JE, Aronoff RJ et al. Inhibition of active sodium transport in erythrocytes from burned patients. Surg Gynecol Obstet 1974 139: 538 540.
123. Simon TL, Curreri PW, Harker LA. Kinetic characterization of hemostasis in thermal injury. J Lab Clin Med 1977 89: 702 711.
124. Cullen JJ, Murray DJ, Kealey GP. Changes in coagulation factors in patients with burns during acute blood loss. J Burn Care Rehabil 1989 10: 517 522.
125. Sheridan RL, Szyfelbein SK. Trends in blood conservation in burn care. Burns 2001 27: 272 276.
126. Ikeda S, Schweiss JF. Maximum infusion rates and CVP accuracy during high-flow delivery through multilumen catheters. Crit Care Med 1985 13: 586 588.
127. Nissenson AR, Strobos J. Iron deficiency in patients with renal failure. Kidney Int Suppl 1999 69: S18 S21.
128. Montini G, Zacchello G, Baraldi E et al. Benefits and risks of anemia correction with recombinant human erythropoietin in children maintained by hemodialysis. J Pediatr 1990 117: 556 560.
129. Chavers BM, Sullivan EK, Tejani A et al. Pre-transplant blood transfusion and renal allograft outcome: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 1997 1: 22 28.
130. Butt ML, Shafi T, Farooqi I et al. Effect of dialysis on bleeding time in chronic renal failure. J Pak Med Assoc 1998 48: 242 244.
131. Remuzzi G, Livio M, Marchiaro G et al. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron 1978 22: 347 353.
132. Mannucci PM, Remuzzi G, Pusineri F et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983 308: 8 12.
133. Bontempo FA, Lewis JH, Van Thiel DH et al. The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation 1985 39: 532 536.
134. Carlier M, Van Obbergh LJ, Veyckemans F et al. Hemostasis in children undergoing liver transplantation. Semin Thromb Hemost 1993 19: 218 222.
135. Eckhoff DE, D'Alessandro AM, Knechtle SJ et al. 100 consecutive liver transplants in infants and children: an 8-year experience. J Pediatr Surg 1994 29: 1135 1139.
136. Kalayoglu M, D'Alessandro AM, Sollinger HW et al. Experience with reduced-size liver transplantation. Surg Gynecol Obstet 1990 171: 139 147.
137. Basford TJ, Poenaru D, Silva M. Comparison of delayed complications of central venous catheters placed surgically or radiologically in pediatric oncology patients. J Pediatr Surg 2003 38: 788 792.
138. Randolph AG, Cook DJ, Gonzales CA et al. Ultrasound guidance for placement of central venous catheters: a meta-analysis of the literature. Crit Care Med 1996 24: 2053 2058.
139. Goodnough LT, Brecher ME, Kanter MH et al. Transfusion medicine. First of two parts-blood transfusion. N Engl J Med 1999 340: 438 447.
140. Goodnough LT, Brecher ME, Kanter MH et al. Transfusion medicine. Second of two parts - blood conservation. N Engl J Med 1999 340: 525 533.
141. Mayer MN, de Montalembert M, Audat F et al. Autologous blood donation for elective surgery in children weighing 8-25 kg. Vox Sang 1996 70: 224 228.
142. Copley LA, Richards BS, Safavi FZ et al. Hemodilution as a method to reduce transfusion requirements in adolescent spine fusion surgery. Spine 1999 24: 219 222.
143. Goodnough LT. Erythropoietin therapy versus red cell transfusion. Curr Opin Hematol 2001 8: 405 410.
144. Rosencher N, Ozier Y. [Peri-operative use of EPO]. Transfus Clin Biol 2003 10: 159 164.
145. Tamir L, Fradin Z, Fridlander M et al. Recombinant human erythropoietin reduces allogeneic blood transfusion requirements in patients undergoing major orthopedic surgery. Haematologia (Budap) 2000 30: 193 201.
146. Feagan BG, Wong CJ, Kirkley A et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000 133: 845 854.
147. Horiba K, Itou Y, Terada H et al. Experience of predeposit autologous blood transfusion and medication of recombinant human erythropoietin in pediatric open heart surgery. Kyobu Geka 1991 44: 1146 1150.
148. Ley SJ. Intraoperative and postoperative blood salvage. AACN Clin Issues 1996 7: 238 248.
149. Napier JA, Bruce M, Chapman J et al. Guidelines for autologous transfusion. II. Perioperative haemodilution and cell salvage. British Committee for Standards in Haematology Blood Transfusion Task Force. Autologous Transfusion Working Party. Br J Anaesth 1997 78: 768 771.
150. Elias D, Lapierre V, Billard V. Perioperative autotransfusion with salvage blood in cancer surgery. Ann Fr Anesth Reanim 2000 19: 739 744.